Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.
This program is intended for healthcare professionals only.
Professor Mark Swain discusses the latest updates from the ASSURE trial of seladelpar, presented at EASL 2024, in Milan, Italy. Explore key findings on efficacy, safety, and interim long-term results of this study.
Like this content?
Share with a colleague
This program is made possible thanks to an independent educational grant from Ipsen.
Email: [email protected]